Novartis Application for Expanded Menveo Indication from 2 Months of Age Accepted for Review by FDA

Novartis NVS announced today that the US Food and Drug Administration has accepted for review its supplemental Biologics License Application to expand the Menveo indication to include infants and toddlers from 2 months of age. Menveo is already approved in the US for use in individuals 2 years to 55 years of age.